China's New Five-Year Plan Targets Global Biopharma Leadership

By Adrian Cole

China has announced a new five-year plan, spanning 2026 to 2030, with ambitious targets to elevate its biopharma industry on the global stage. This initiative, issued by the Ministry of Industry and Information Technology (MIIT) alongside nine other central authorities, aims to position China as a leader in biomedical research and development.

The plan outlines specific goals, including achieving global annual sales exceeding USD 1 billion for at least five Chinese-developed drugs. Additionally, it aims for first-in-class drugs developed in China to constitute at least 25% of the global total. The innovative drug sector is expected to grow at an average annual rate of at least 20%.

This strategic plan builds on the previous five-year bioeconomy plan (2021–2025), which emphasized integrating biotechnology with information technology and fostering international collaboration. The earlier plan aimed for bioeconomy to become a key driver of high-quality development by 2025, setting the groundwork for the current focus on biopharma commercialization and global competitiveness.